108
|
349
|
4fv6A |
Crystal structure of the erk2 complexed with e57 |
103
|
348
|
4fv0A |
Crystal structure of the erk2 complexed with ek3 |
105
|
347
|
4fv3A |
Crystal structure of the erk2 complexed with ek6 |
105
|
348
|
4fuyA |
Crystal structure of the erk2 complexed with ek2 |
105
|
346
|
4fv1A |
Crystal structure of the erk2 complexed with ek4 |
103
|
350
|
4fv9A |
Crystal structure of the erk2 complexed with e71 |
105
|
347
|
4fuxA |
Crystal structure of the erk2 complexed with e75 |
111
|
350
|
4fv8A |
Crystal structure of the erk2 complexed with e63 |
98
|
349
|
4fv5A |
Crystal structure of the erk2 complexed with ek9 |
108
|
347
|
4fv2A |
Crystal structure of the erk2 complexed with ek5 |
103
|
349
|
4fv4A |
Crystal structure of the erk2 complexed with ek7 |
111
|
350
|
4fmqA |
Crystal structure of human erk2 complexed with a mapk docking peptide |
121
|
346
|
3qyzA |
Crystal structure of erk2 in complex with an inhibitor |
114
|
346
|
3qywA |
Crystal structure of erk2 in complex with an inhibitor |
114
|
355
|
3r63A |
Structure of erk2 (spe) mutant (s246e) |
106
|
349
|
3queA |
Human p38 map kinase in complex with skepinone-l |
107
|
351
|
3qudA |
Human p38 map kinase in complex with 2-amino-phenylamino-benzophenone |
109
|
356
|
3pzeA |
Jnk1 in complex with inhibitor |
112
|
357
|
3py3A |
Crystal structure of phosphorylated p38alpha map kinase |
107
|
348
|
3p79A |
P38 inhibitor-bound |
98
|
356
|
3ptgA |
Design and synthesis of a novel, orally efficacious tri-substituted thiophene based jnk inhibitor |
108
|
350
|
3pg3A |
Human p38 map kinase in complex with rl182 |
100
|
348
|
3p7aA |
P38 inhibitor-bound |
103
|
348
|
3p78A |
P38 inhibitor-bound |
106
|
348
|
3p7bA |
P38 inhibitor-bound |
100
|
348
|
3p7cA |
P38 inhibitor-bound |
95
|
355
|
3oxiA |
Design and synthesis of disubstituted thiophene and thiazole based inhibitors of jnk for the treatment of neurodegenerative diseases |
105
|
350
|
3p4kA |
The third conformation of p38a map kinase observed in phosphorylated p38a and in solution |
106
|
355
|
3oy1A |
Highly selective c-jun n-terminal kinase (jnk) 2 and 3 inhibitors with in vitro cns-like pharmacokinetic properties |
105
|
348
|
3p5kA |
P38 inhibitor-bound |
102
|
348
|
3objA |
Conformational plasticity of p38 map kinase dfg mutants in response to inhibitor binding |
99
|
348
|
3o8uA |
Conformational plasticity of p38 map kinase dfg motif mutants in response to inhibitor binding |
92
|
350
|
3odzX |
Crystal structure of p38alpha y323r active mutant |
109
|
346
|
3o71A |
Crystal structure of erk2/dcc peptide complex |
101
|
348
|
3oc1A |
Conformational plasticity of p38 map kinase dfg motif mutants in response to inhibitor binding |
110
|
347
|
3o8pA |
Conformational plasticity of p38 map kinase dfg motif mutants in response to inhibitor binding |
113
|
349
|
3nwwA |
P38 alpha kinase complexed with a 2-aminothiazol-5-yl-pyrimidine based inhibitor |
110
|
348
|
3oefX |
Crystal structure of y323f inactive mutant of p38alpha map kinase |
96
|
349
|
3od6X |
Crystal structure of p38alpha y323t active mutant |
102
|
348
|
3o8tA |
Conformational plasticity of p38 map kinase dfg-motif mutants in response to inhibitor binding |
102
|
357
|
3o17A |
Crystal structure of jnk1-alpha1 isoform |
99
|
349
|
3ocgA |
P38 alpha kinase complexed with a 5-amino-pyrazole based inhibitor |
92
|
350
|
3odyX |
Crystal structure of p38alpha y323q active mutant |
94
|
348
|
3obgA |
Conformational plasticity of p38 map kinase dfg mutants in response to inhibitor binding |
111
|
358
|
3o2mA |
Crystal structure of jnk1-alpha1 isoform complex with a biaryl tetrazol (a-82118) |
103
|
348
|
3newA |
P38-alpha complexed with compound 10 |
106
|
348
|
3nnxA |
Crystal structure of phosphorylated p38 alpha in complex with dp802 |
111
|
348
|
3nnvA |
Crystal structure of p38 alpha in complex with dp437 |
112
|
348
|
3nnuA |
Crystal structure of p38 alpha in complex with dp1376 |
113
|
349
|
3nnwA |
Crystal structure of p38 alpha in complex with dp802 |